Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

ogram for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of its technology platform, the potential of NKTR-102 for breast cancer patients, preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the Phase 2 data for NKTR-102 in breast cancer in this press release remain subject to audit and confirmation procedures, and the final results may change materially and adversely after such procedures are completed; (iii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in metastatic breast cancer including but not limited to final progression-free survival and overall survival and therefore the complete and final results for this study may diff
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ), ... and Chief Executive Officer, will preside over the NASDAQ ... first day of Breast Cancer Awareness Month. In his ... on the important benefits of Hologic,s 3D Mammography technology, ... clinically superior to traditional mammography. This is ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
(Date:10/1/2014)... 01, 2014 Two bicyclists began a ... across the country in an effort to raise funds ... The cyclists, a father-daughter team, plan to bike ... Blaine, Washington and finishing in Key West Florida. ... The Warriors®, a national nonprofit organization that assists post-9/11 ...
(Date:10/1/2014)... UP4 Probiotics will be donating a portion ... National Network to End Domestic Violence ( http://www.nnedv.org ) ... through nationwide polling that took place during August and ... , “We are proud to have been chosen by ... of UP4 Women’s Probiotics during the month of October,” ...
(Date:10/1/2014)... 2014 After a run of successful ... emerging filmmaker Jacqui Blue is continuing her mission to ... truth about natural birth. The documentary has received a ... world and has been an effective medium for starting ... highlighted in the film provide a wealth of information ...
(Date:10/1/2014)... Looking for holiday gift ideas? Éminence Organic ... gift giving easy this holiday season. Starting October 1st 2014, ... solve all shopping dilemmas. Choose from two luxury skin care ... the delicate eye area or to deliver whole body beauty. ... Rescue Duo Gift Set are formulated to suit all skin ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 The annual ... levels again in 2015, says a new forecast by ... most recent consumer price index (CPI) data through August, TSCL ... “That would make the sixth consecutive year of record low ... the COLA first became automatic in 1975,” he notes. , ...
Breaking Medicine News(10 mins):Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Research (AADR) has announced Irwin D. Mandel, AADR past president ... of the inaugural 2010 AADR Distinguished Mentoring Award. This award ... in Washington, DC, March 3, 2010. Mandel began ... up his part-time private practice in 1968 to devote himself ...
... could lead to new treatments, study suggests , FRIDAY, Feb. ... for cystic fibrosis, U.S. researchers have identified a defective signaling ... disease. , Cystic fibrosis causes thick, sticky mucus to build ... of the most common potentially lethal genetic diseases in children ...
... ... ... ... ...
... ... ... the release of the 2010 U.S. Ambulatory EHR Study, a strategic analysis of the U.S. ... (HITECH) component of the American Recovery and Reinvestment (ARRA) Act. ,As recently presented at the ...
... they closely matched the real personalities of the profile ... the notion that Internet users favor idealized virtual identities, ... networking sites such as Facebook create profiles that stick ... networks may be more interested in fostering real communication ...
... ... ... ... ...
Cached Medicine News:Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2Health News:Facebook Profiles Don't Stretch the Truth 2Health News:Facebook Profiles Don't Stretch the Truth 3Health News:Facebook Profiles Don't Stretch the Truth 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 2Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 3Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 5Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 6Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 7Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 8Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 9Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 10Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 11Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 12Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 13Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 14Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 15Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 16
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
... is indicated for use in the thoracolumbar spine ... or excised for the treatment of tumors, to ... neural tissues, and to restore the height of ... also indicated for treating fractures of the thoracic ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
Medicine Products: